Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

May 03, 2022; 98 (18 Supplement) Thursday, April 7

Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi-National Registry (P17-4.001)

Sifat Sharmin, Charles Malpas, Izanne Roos, Ibrahima Diouf, Raed Alroughani, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Murat Terzi, Cavit Boz, Bassem Yamout, Samia J. Khoury, Marco Onofrj, Alessandra Lugaresi, Ayse Altintas, Alexandre Prat, Marc Girard, Pierre Duquette, Maria Jose Sa, Daniele Spitaleri, Youssef Sidhom, Riadh Gouider, Aysun Soysal, Recai Turkoglu, Maria Pia Amato, Yara Fragoso, Tomas Kalincik
First published May 3, 2022,
Sifat Sharmin
1University of Melbourne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Malpas
1University of Melbourne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Izanne Roos
1University of Melbourne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ibrahima Diouf
1University of Melbourne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raed Alroughani
2Amiri Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serkan Ozakbas
3Dokuz Eylul University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillermo Izquierdo
4Hospital Universitario Virgen Macarena
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Eichau
4Hospital Universitario Virgen Macarena
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana Horakova
5Charles University in Prague
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Kubala Havrdova
5Charles University in Prague
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Patti
6University of Catania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murat Terzi
719 Mayis University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cavit Boz
8KTU Medical Faculty Farabi Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bassem Yamout
9American University of Beirut Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samia J. Khoury
9American University of Beirut Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Onofrj
10University G. d’Annunzio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandra Lugaresi
11Università di Bologna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayse Altintas
12Koc University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre Prat
13Universite de Montreal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Girard
13Universite de Montreal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Duquette
13Universite de Montreal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Jose Sa
14Universitario de Sao Joao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniele Spitaleri
15Nazionale San Giuseppe Moscati Avellino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youssef Sidhom
16Razi Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Riadh Gouider
16Razi Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aysun Soysal
17Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Recai Turkoglu
18Haydarpasa Numune Training and Research Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Pia Amato
19University of Florence
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yara Fragoso
20Universidade Metropolitana de Santos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas Kalincik
1University of Melbourne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi-National Registry (P17-4.001)
Sifat Sharmin, Charles Malpas, Izanne Roos, Ibrahima Diouf, Raed Alroughani, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Murat Terzi, Cavit Boz, Bassem Yamout, Samia J. Khoury, Marco Onofrj, Alessandra Lugaresi, Ayse Altintas, Alexandre Prat, Marc Girard, Pierre Duquette, Maria Jose Sa, Daniele Spitaleri, Youssef Sidhom, Riadh Gouider, Aysun Soysal, Recai Turkoglu, Maria Pia Amato, Yara Fragoso, Tomas Kalincik
Neurology May 2022, 98 (18 Supplement) 2668;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: We sought to identify the early predictors of disability progression in a multi-national cohort of patients with paediatric-onset multiple sclerosis (POMS), considering the potential for commencing high-efficacy disease-modifying therapies (DMTs).

Background: Early recognition of markers of faster disability worsening in POMS is important for treatment decisions at the earliest possible time after symptoms onset.

Design/Methods: We identified patients who were <18 years at the onset of MS symptoms from the global MSBase registry. Patients with first neurological assessment within 12 months from symptoms onset were included. The variables examined as predictors of future MS Severity Score (MSSS; disability ranked by disease duration) included: age at symptoms onset, complete recovery from first relapse, EDSS score, relapse phenotypes and frequency during the first 12 months. The analyses were adjusted for cumulative proportion of time on high-efficacy DMTs. A Bayesian log-normal generalized linear mixed model was used to analyse the longitudinal data.

Results: 672 patients (70% women) contributing 9357 visits were included. The median (quartiles) age at symptoms onset was 16 (15–17) years. Older age at symptoms onset (exp(β)=1.09 [95% Credible Interval: 1.03,1.16]), higher EDSS score (1.25 [1.13,1.36]), and pyramidal (1.34 [1.13,1.58]), visual (1.28 [1.10,1.48]), and cerebellum (1.17 [1.00,1.39]) symptoms during the first 12 months were associated with higher MSSS. Interestingly, MSSS was reduced by 4% for each unit increase in the proportion of time on high-efficacy DMTs (0.96 [0.93,0.99]).

Conclusions: MS symptoms presented later in the childhood, higher disability, and pyramidal, visual, or cerebellum symptoms during the first year predicted significant worsening in disability in patients with paediatric MS. Persistent treatment with high-efficacy DMTs was associated with reduced rate of disability worsening.

Disclosure: Dr. Sharmin has nothing to disclose. Charles Malpas has nothing to disclose. Izanne Roos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Izanne Roos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Izanne Roos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Izanne Roos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Izanne Roos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Izanne Roos has received research support from MSIF-ARSEP. Izanne Roos has received research support from Melbourne Research Scholarship. Izanne Roos has received personal compensation in the range of $0-$499 for serving as a travel support with Merck. Izanne Roos has received personal compensation in the range of $0-$499 for serving as a travel support with Roche. Ibrahima Diouf has nothing to disclose. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Bayer, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen, Novartis, Merck, Roche, Sanofi. Dr. Ozakbas has nothing to disclose. Dr. Izquierdo Ayuso has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer, Biogen Idec, Novartis, Sanofi, Merck Serono, Roche, Actelion and Celgene. Dr. Izquierdo Ayuso has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme, Novartis, Sanofi Aventis, Alexion. Sara Eichau Madueño has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Sara Eichau Madueño has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Sara Eichau Madueño has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Sara Eichau Madueño has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Sara Eichau Madueño has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Sara Eichau Madueño has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Sara Eichau Madueño has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Sara Eichau Madueño has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Sara Eichau Madueño has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Sara Eichau Madueño has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Merck. Sara Eichau Madueño has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Sara Eichau Madueño has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Sara Eichau Madueño has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Sara Eichau Madueño has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Sara Eichau Madueño has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Actelion. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Actelion. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Havrdova has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Biogen. Dr. Patti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Almirall, Bayer, Biogen, Merck, Roche, Sanofi, TEVA. Dr. Patti has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for University of Catania and AISM/FISM, Fondazione Italiana Sclerosi Multipla. Dr. Terzi has nothing to disclose. Dr. Boz has nothing to disclose. Dr. Yamout has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Yamout has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Yamout has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Yamout has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Yamout has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Khoury has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merk. Dr. Khoury has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Khoury has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ANA. Dr. Khoury has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Clinical Immunology. The institution of Dr. Khoury has received research support from MENACTRIMS. The institution of Dr. Khoury has received research support from NMSS. The institution of Dr. Khoury has received research support from Office of Naval Research USA. An immediate family member of Dr. Khoury has received intellectual property interests from a discovery or technology relating to health care. Dr. Onofrj has nothing to disclose. Dr. Lugaresi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck Serono. Dr. Lugaresi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis Pharma. Dr. Lugaresi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Lugaresi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Lugaresi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Lugaresi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Lugaresi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mylan. Dr. Lugaresi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Sqibb. Dr. Lugaresi has a non-compensated relationship as a Speaker at meetings, participant in trials with Fondazione Italiana Sclerosi Multipla that is relevant to AAN interests or activities. Dr. Altintas has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck . Dr. Altintas has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Deva. The institution of Dr. Altintas has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Prat has received research support from CIHR and MSSC. Dr. Girard has nothing to disclose. The institution of Dr. Duquette has received research support from Biogen and Genzyme. Maria Jose Marques de Sa, Prof has nothing to disclose. Samia Ben Sassi has nothing to disclose. Dr. Sidhom has nothing to disclose. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Gouider has received research support from Clinical Investigation Center. The institution of Dr. Gouider has received research support from Menactrims. Dr. Soysal has nothing to disclose. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi genzyme. The institution of Dr. Amato has received research support from Merck. The institution of Dr. Amato has received research support from Biogen. The institution of Dr. Amato has received research support from Roche. Yara D. Fragoso has nothing to disclose. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving as a Consultant for National Health and Medical Research Council. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MS Research Australia. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for WebMD Global. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for BioCSL. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. The institution of Tomas Kalincik has received research support from Biogen. The institution of Tomas Kalincik has received research support from Novartis. The institution of Tomas Kalincik has received research support from Genzyme. The institution of Tomas Kalincik has received research support from Roche. The institution of Tomas Kalincik has received research support from Celgene. The institution of Tomas Kalincik has received research support from Merck. The institution of Tomas Kalincik has received research support from MSBase Foundation. The institution of Tomas Kalincik has received research support from ARSEP and EDMUS Foundations. The institution of Tomas Kalincik has received research support from MS Research Australia. The institution of Tomas Kalincik has received research support from National Health and Medical Research Council. The institution of Tomas Kalincik has received research support from Australian Research Council. The institution of Tomas Kalincik has received research support from MS Society. The institution of Tomas Kalincik has received research support from Trish Foundation. Tomas Kalincik has a non-compensated relationship as a scientific leadership group chair with MSBase Foundation that is relevant to AAN interests or activities.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology

Dr. Babak Hooshmand and Dr. David Smith

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 101 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise